Post-Market Registry Evaluating BAROSTIM THERAPY with the CE-Marked BAROSTIM NEO System in Heart Failure with Reduced Ejection Fraction
Led by CVRx, Inc. · Updated on 2026-09-11
500
Participants Needed
30
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting.
Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure.
During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.
CONDITIONS
Brief Title
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
Research Team
N
Nicole Baumann
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Carotid atherosclerosis greater than 50% by ultrasound or angiographic evaluation
Ulcerative plaques in the carotid artery by ultrasound or angiographic evaluation
Your Study Journey
Screening
Duration - Up to 30 days before enrollment
Participants are screened for eligibility to participate in the trial.
Monitoring and Follow-up
Duration - 12 months after implant
Participants undergo standard care assessments before implant and at 3, 6, and 12 months after receiving the BAROSTIM NEO System implant. These include heart function tests, exercise capacity evaluations, and blood biomarker measurements. Hospitalizations related to heart failure are also tracked.
Visits at baseline, 3, 6, and 12 months post-implant
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase 2 Study of 18F-mFBG PET Imaging
for Heart Failure Patients with Ischemic Cardiomyopathy
and Implantable Cardioverter-Defibrillators
Post-Discharge Counseling and Phone Follow-Up to Reduce Heart Failure Readmissions at Komfo Anokye Teaching Hospital
Myocardial Energetic Profiling Using 31P Magnetic Resonance Spectroscopy
and Prognostic Assessment Across Heart Failure and Cardiomyopathy Types
3D Imaging Study of Right Heart Function During Mechanical Pump Placement for Heart Failure
Evaluating Cardiac Fibrosis in Heart Failure Using 68Ga-FAPI PETCT Compared to MRI
A Pilot Study in Patients with HFrEF and HFpEF
Study of Vascular Function and Exercise Effects in Aging and Cardiovascular Diseases Including COPD and Pulmonary Hypertension
A Phase I Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Effects of Oral Doses of HRS-5765 in Healthy Adults Aged 18 to 65
Phase I Study Evaluating Safety and Pharmacokinetics of Single and Multiple Oral Doses of HRS-7156 in Healthy Adults
Optimizing Heart Failure and Chronic Kidney Disease Treatment in Elderly Patients Using Sodium Zirconium Cyclosilicate to Manage Potassium Levels
Danish Study Testing Coenzyme Q10 and Selenium Supplements to Reduce Hospitalization and Death in Heart Failure Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
Michael R Zile, William T Abraham, Fred A Weaver...
Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study.